| INTRODUC TI ON
Acute myeloid leukemia (AML) is the most common acute leukemia in adults with an incidence of approximately 3-5 cases per 100 000 individuals. [1] [2] [3] Approximately 20 000 new cases are diagnosed annually, half of which will die from this disease. 2 The World Health
Organization groups AML with recurrent genetic abnormalities into 11 subtypes based on specific chromosomal rearrangements and genetic mutations. 4 An additional category characterized by recurrent cytogenetic abnormalities, including unbalanced copy number variation (CNVs), is defined as "AML with myelodysplasia-related changes". 3 The identification of these well-characterized recurrent genomic abnormalities provides important diagnostic, prognostic, and treatment-related information.
Currently, most genomic testing of bone marrow or blood speci- (Table S1) , and each probe set requires an independent, costly, and time-consuming validation. 5, 6 Despite their size, these panels still have the potential to miss cryptic gene fusions resulting from insertional events. While FISH has a higher resolution (100-200 kb compared to >5 Mb) than karyotyping, its resolution is inferior compared to newer methodologies such as chromosomal microarray and NGS technologies, which have the potential to provide more precise characterization of chromosomal abnormalities.
We explored the ability of an NGS methodology, mate pair sequencing (MPseq), to overcome the limitations of conventional karyotyping and FISH studies. MPseq is a whole-genome sequencing assay that utilizes long input DNA (2-5 Kb) that is circularized and fragmented to the size of paired-end fragments (200-500 bp). 
| Conventional chromosome analysis

| Fluorescence in situ hybridization (FISH)
Commercial and "laboratory-developed" (LD) dual-color dual-fusion (D-FISH), break-apart and enumeration FISH probes were utilized to detect AML-specific abnormalities (Table S1 ). All specimens were subjected to standard FISH pretreatment, hybridization, and fluorescence microscopy according to specimen-specific protocols. Methods were described in the manuscripts by Aypar et al 5 and Keefe et al. 6 FISH analysis was performed by qualified clinical cytogenetic technologists and interpreted by a board-certified clinical cytogeneticist.
| DNA extraction and library preparation
The DNA extraction and mate pair library preparation methods 
| Structural variant bioinformatics pipeline
These and the remaining methods were described in the manuscripts by Johnson et al 7 and Smadbeck et al. 8 MPseq data were processed using BIMA to map to the reference genome and SVAtools for breakpoint detection of both junctions in chromosomal rearrangements and copy number changes (process outlined in Figure 1 ). BIMA is a binary indexing mapping algorithm for simultaneous mapping of both reads in a mate pair fragment 9 and was used to map all MPseq fragments to reference genome GRCh38 using default settings. BIMA is tuned to detect reads that map to two discontinuous genomic areas, such as when a read crosses a breakpoint or a biotin-junction (common in NGS mate pair library preparation).
Structural variation (SV) was detected by SVAtools, which utilizes the BIMA output to detect and report the breakpoints of structural variants. SVAtools combines three algorithmic approaches:
read-pair, split-read, and read depth/count. SVAtools detects junc- Bridged coverage will depend on the number of fragments and the length the fragments (read lengths plus insert length). Given the bridged coverage of these samples, the reported breakpoints are estimated to be within 200 bps when a split read is not present. 
| Structural variation visualization
Junctions and CNVs were graphically illustrated using genome, junction and region plots as described in Johnson, et al. 7 We re- Figure 2 ). This restriction was necessary for the validation of the MPseq assay by comparing it to the gold standard FISH assay and FISH probes were available for the above-listed targets. In addition, interstitial CNV regions with no supporting junction, and losses <200 kb and gains <500 kb were not reported.
Location of breakpoints identified in each gene from MPseq is indicated along with the specific transcript determined by the consensus transcript from the St. Jude's PeCan Data Portal (Table S3) .
| RE SULTS
To establish the MPseq assay's limits of detection, we evaluated the minimum requirements for (a) DNA input, (b) number of sequenced fragments, and (c) tumor percentage (Supplemental Data,
Figures S1-S5 and summarized in Table S2 ). In summary, eleven samples tested with decreasing amounts of input DNA indicated that the minimum amount yielding accurate results was 0.5 µg ( Figure   S3 ). In silico dilution studies of six samples with various rearrangements/CNVs determined that a minimum of 20 million sequenced fragments were required to ensure detection of all targeted abnormalities ( Figure S4 ). Tumor content requirements were assessed by performing various dilutions of six samples with known rearrangements/CNVs, and established a minimum of 10% tumor for the detection of rearrangements and 25% tumor for the detection of CNVs ( Figure S5 ).
| Detection of primary cytogenetic abnormality using MPseq
We Table S2 ).
All 68 abnormal samples demonstrated concordance with known FISH studies when the abnormal FISH percentage was greater than 10% for rearrangements and greater than 25% for CNVs (Table S2) .
Three samples (2-PB, 8-BM and 40-BM) were positive for trisomy 8 (each with FISH percentage less than 9%) but were not detected by MPseq (Table 1) . Twenty apparently normal samples were also evaluated by MPseq and 19 of 20 were found to be concordant (95%) with no AML-panel abnormalities identified (Table 2 ).
| MPseq clarified gene fusions when fish was abnormal
MPseq was necessary to more clearly define the specific gene fusion in eight (12%) of the 68 abnormal cases when FISH either revealed a gene break-apart pattern or three abnormal signals ( In four cases, MPseq identified the NUP98 fusion partner (either PSIP1 or SETBP1 in one case each or KDM5A in two cases) when FISH identified a NUP98 break-apart pattern (no knowledge of the fusion partner). Thus, MPseq was necessary to molecularly define a subset of abnormalities that would not have been elucidated using our current AML FISH panel.
fragments with blue in the forward orientation and red in the reverse. Copy state is shown by the gray shaded area on the far top and bottom of the plot. All this data taken together allows for reconstruction of the abnormal region
| MPseq detected cryptic rearrangements missed by conventional cytogenetic assays
In two cases, MPseq identified cryptic rearrangements that were not apparent using conventional cytogenetic tests. Sample (78-BM) was initially classified as a normal sample for this verification (Table 2) because we reported a normal karyotype and normal AML FISH panel result. However, the mate pair data specifically demonstrated the insertion of exons 9-24 of MLLT10 into intron 9 of KMT2A resulting from a cryptic, insertional rearrangement which was later confirmed using a MLLT10/KMT2A D-FISH probe and not visible by karyotype or by the break-apart KMT2A FISH probe ( Figure 3 and [10] [11] [12] While this case was considered concordant in this validation study, we identified a "cryptic" MECOM/RPN1 fusion later confirmed by FISH.
| D ISCUSS I ON
MPseq provided further value in cases where we identified additional FISH signals or a FISH break-apart result without the availability of a reflex FISH probe to further define a suspected rearrangement. One example (case 1-PB) is the identification of an TA B L E 1 Accuracy results from 68 known abnormal samples extracted from either fresh bone marrow (n = 27), fresh peripheral blood (n = 25), or fixed cell pellets (n = 16) 45,XX,add(1)(p22),add(2)(p13),der(4)t(1;4)(p32;q21),-5,inv(6) (p11.2q21),t(9;11)(p22;p15),-12,add(12)(p13),add(15) (p15),add(16)(q22),add (17) (Table 3) was filtered to reveal only the abnormalities on our predefined AML-panel filter. Future studies are underway to identify novel abnormalities throughout the genome associated with myeloid malignancies. As novel rearrangements and copy number alterations important in AML are uncovered in the future, the clinical MPseq panel can be easily expanded to include additional targets.
The studies presented here demonstrate the value of MPseq as a novel NGS-based technology that has the potential to revolutionize the diagnosis of hematologic malignancies and provide an opportunity to advance precision medicine.
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